Aptevo Therapeutics Inc., a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company's marketed products also comprise VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals; and IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates include MOR209/ES414, ES210, ES425, and otlertuzumab used to expand on the utility and effectiveness of therapeutic antibodies; and 5E3 mAb, a monoclonal antibody therapeutic that is in pre-clinical development for Alzheimer's disease. The company was incorporated in 2016 and is based in Seattle, Washington. As of August 01, 2016, Aptevo Therapeutics Inc. operates independently of Emergent BioSolutions, Inc.

Aptevo Therapeutics Inc

Aptevo Therapeutics, Inc. focuses on novel oncology and hematology therapeutics to meaningfully improve patient's lives. It also products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immune-oncology. Aptevo Therapeutics was founded on February 22, 2016 and is headquartered in Seattle, WA.

Should you buy, sell, or hold Aptevo Therapeutics Inc (APVO) ?

Aptevo Therapeutics Inc (APVO) : Buy or Sell